Genetically modified pigs having at least one cancer and/or at least one co-morbid condition are provided. Also provided are methods of using the pig and derived tumor cells to screen for therapeutic compounds, medical devices or procedures, and/or combinations thereof. Further provided are methods of producing personalized cancer models, including obtaining a tumor sample from a subject, identifying mutations in the tumor sample, and producing a genetically modified tumor or tumor cell line having the same mutations.

The present invention encompasses treatments for neurologic disorders with recombinant vims vectors encoding G-protein coupled receptors. In particular, the invention is directed to the treatment of addiction disorders including but not limited to alcohol addiction and opiate addiction.

This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system (CNS).

Method for selecting mammalian cells having a genetically-desirable trait, the method comprising culturing an embryo in vitro, dividing the cells from the embryo into aliquots, subjecting the cells from at least one of the aliquots to a genetic analysis, and, based on the results of such analysis, selecting an aliquot of cells. Method for selecting mammalian cells having a genetically-desirable trait, the method comprising culturing an embryo in vitro, transferring the cultured embryo into a recipient female, collecting the embryo, dividing the cells from the embryo into aliquots, subjecting the cells from at least one of the aliquots to a genetic analysis, and, based on the results of such analysis, selecting an aliquot of cells. Method for selecting a mammalian embryo having a genetically-desirable trait, the method comprising removing one or more cells from each of a plurality of embryos, culturing the cells, subjecting the cultured cells to a genetic analysis, and, based on the results of such analysis, selecting an embryo.

Genetic tests, such as whole genome analysis (WGA), have been employed to identify genetically superior embryos. The disclosed methods extend in vitro culture time of embryos while awaiting results of genetic tests being performed on a portion of the same embryos. The disclosed methods also help expand the number of cells in each embryo before implantation in the recipient.

Provided herein are methods for preventing or treating diseases, said methods comprising (i) inhibiting entry of bacteriophages and/or component(s) thereof into microbiota, bodily fluid(s) or tissue(s) of the mammals and/or (ii) inactivating or modifying bacteriophages and/or component(s) thereof present in microbiota, bodily fluid(s) or tissues of the mammals and/or (iii) inactivating or modifying bacteriophages and/or component(s) thereof in one or more of food, drinking water, water for washing, water for air humidification, air, or habitat object of the mammals.

This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system (CNS).

The invention is directed to an animal marking and treatment apparatus. The marking apparatus is an animal treatment apparatus to apply an animal treatment to a surface or subcutaneous layer of an animal via an operative end. The marking apparatus includes a marking portion, attached to the animal treatment apparatus, and located at the operative end. The marking apparatus is located such that when the animal receives the treatment the marking portion marks the animal by stamping at the same time.

An object of the present invention is to provide a method which constantly enables organ regeneration for the purpose of achieving organ regeneration with higher efficiency. It has been discovered that, in a blastocyst complementation method, a next generation is born when a deficiency in an organ, such as pancreas and kidney, is complemented by injection of ES cells into a generated blastocyst, and further discovered that a transgenic animal having a pancreas or a kidney thus complemented can transmit the phenotype to the next generation as a founder. This discovery has revealed that organ regeneration can be accomplished by using such a founder. Thus, the present invention achieved the above-described object.

The invention is directed to an animal marking and treatment apparatus. The marking apparatus is an animal treatment apparatus to apply an animal treatment to a surface or subcutaneous layer of an animal via an operative end. The marking apparatus includes a marking portion, attached to the animal treatment apparatus, and located at the operative end. The marking apparatus is located such that when the animal receives the treatment the marking portion marks the animal by stamping at the same time.